AVXL
Anavex Life Sciences Corp.
Set alert
- YTD
- -66.57%
- 1 year
- -85.18%
- Open
- 1.30
- Prev close
- 1.30
- Mkt cap
- 110.31M
- Vol
- 1.20M
- Avg vol
- 1.04M
- EPS
- -0.14
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.18
- High
- 1.30
- Forward P/E
- -17.25
- Beta
- 0.60
- Short ratio
- 10.82
- Inst. own
- 32.04%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 7.73
- 200-d avg
- 5.65
- 1y target
- 35.47
Key statistics
- Market cap
- 921.73M
- Enterprise value
- 593.03M
- Trailing P/E
- 0.00
- Forward P/E
- -17.25
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 7.10
- EPS (TTM)
- -0.52
- Beta
- 0.60
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -19.06M
- Total cash
- 138.76M
- Total debt
- 0
- Return on equity
- -30.03%
- Shares outstanding
- 84.80M
- Short % of float
- 23.96%
- 50-day average
- 7.73
- 200-day average
- 5.65
Analyst view
Consensus: strong buy
- Target (low)
- 15.00
- Target (mean)
- 35.47
- Target (high)
- 46.00
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.19.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 27, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 26, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 25, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 31, 2024 | EF Hutton | main | Buy | Buy |
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- anavex.com
News
- ANAVEX DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Anavex Life Sciences Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL
- AVXL UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Anavex (AVXL) Investors of Securities Class Action Lawsuit Deadline on November 30, 2026
- Anavex Deadline: AVXL Investors with Losses in Excess of $100K Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit Filed by The Rosen Law Firm
- ANAVEX DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL
- AVXL CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Anavex (AVXL) Investors of Securities Class Action Lawsuit Deadline on November 30, 2026
- Kaplan Fox Urges Anavex Life Sciences Corp. (AVXL) Investors to Contact the Firm Before the Deadline on November 30, 2026
- ANAVEX DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL
- Kirby McInerney LLP Alerts Investors Who Acquired Anavex Life Sciences Corp. AVXL Securities Between November 26, 2025 and August 28, 2026 of Pending Lawsuit
- DEADLINE ALERT for Fluence Energy, Inc. (FLNC), Qfin Holdings, Inc. (QFIN), Endava plc (DAVA), and Anavex Life Sciences Corp. (AVXL): The Law Offices of Frank R. Cruz Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Anavex Life Sciences Corp. of Class Action Lawsuit and Upcoming Deadlines - AVXL
Your note
Sign in to keep a note on AVXL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DONHAUSER PETER D.O. | Director | Purchase | Jun 13, 2024 | 5,000 |
| MISSLING CHRISTOPHER U | Chief Executive Officer | Sale | Mar 27, 2024 | 1,250,210 |
| THOMAS STEFFEN PHD | Director | Purchase | May 14, 2024 | 5,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.95% | 6,740,696 | 73.27M | Sep 29, 2024 |
| Vanguard Group Inc | 5.59% | 4,740,171 | 51.53M | Sep 29, 2024 |
| State Street Corporation | 3.62% | 3,065,947 | 33.33M | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.22% | 1,883,199 | 20.47M | Sep 29, 2024 |
| NWAM LLC | 1.07% | 910,476 | 9.90M | Sep 29, 2024 |
| Two Sigma Investments, LP | 0.98% | 830,624 | 9.03M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.99% | 2,534,500 | 27.55M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.30% | 1,946,169 | 21.15M | Oct 30, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 1.89% | 1,604,415 | 17.44M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.57% | 1,331,918 | 14.48M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.88% | 746,316 | 8.11M | Aug 30, 2024 |
| iShares Biotechnology ETF | 0.69% | 581,949 | 6.33M | Oct 30, 2024 |